This is consistent with the synergism resulting from the simultaneous targeting of TSPO and p53, which may represent a valuable anticancer therapy to treat GBM, since most GBM phenotypes maintain wild-type p53 and over-express TSPO and MDM2 [98]. This evidence concerns the gene MDM2 and glioblastoma.